Literature DB >> 30103022

Parvovirus B19 in Endomyocardial Biopsy of Patients With Idiopathic Dilated Cardiomyopathy: Foe or Bystander?

Clara Hjalmarsson1, Jan-Åke Liljeqvist2, Magnus Lindh2, K Karason3, Entela Bollano3, Anders Oldfors4, Bert Andersson5.   

Abstract

BACKGROUND: Parvovirus B19 (PVB19) has emerged as one of the viruses possibly inducing chronic myocarditis and subsequent idiopathic dilated cardiomyopathy (IDCM). The aim of this work was to investigate the presence and long-term consequences of PVB19-DNA within myocardial biopsies from patients with IDCM and to compare the findings with those from donor hearts (control group). METHODS AND
RESULTS: Forty hospitalized IDCM patients (age 47 ± 12 y) with mean left ventricular ejection fraction 27 ± 12% were included. The presence of PVB19-DNA in myocardial biopsies and of IgG and IgM antibodies in patient sera was analyzed. The control group consisted of 20 donor hearts. The follow-up time was 112 ± 57 months. PVB19-DNA was found in myocardial biopsies of both patients (73%) and control samples (55%; P = .25).Three deaths and 8 heart transplantations occurred in the IDCM group, and 6 deaths in the control group (ie, the recipients of the control hearts). No difference in transplantation-free survival between the PVB19-DNA positive/negative IDCM patients or transplant recipients was found.
CONCLUSIONS: PVB19-DNA is a common finding in both patients with IDCM and in healthy donor hearts, not affecting prognosis. These findings support the view that PVB19 is an innocent bystander, frequently found in myocardium with low DNA copies, and not a plausible cause of IDCM.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Dilated cardiomyopathy; parvovirus B19; transplantation

Mesh:

Year:  2018        PMID: 30103022     DOI: 10.1016/j.cardfail.2018.07.466

Source DB:  PubMed          Journal:  J Card Fail        ISSN: 1071-9164            Impact factor:   5.712


  11 in total

Review 1.  Viral Myocarditis: Classification, Diagnosis, and Clinical Implications.

Authors:  Fabiola B Sozzi; Elisa Gherbesi; Andrea Faggiano; Eleonora Gnan; Alessio Maruccio; Marco Schiavone; Laura Iacuzio; Stefano Carugo
Journal:  Front Cardiovasc Med       Date:  2022-06-20

2.  Nucleoside Analogue Reverse Transcriptase Inhibitors Improve Clinical Outcome in Transcriptional Active Human Parvovirus B19-Positive Patients.

Authors:  Heinz-Peter Schultheiss; Thomas Bock; Heiko Pietsch; Ganna Aleshcheva; Christian Baumeier; Friedrich Fruhwald; Felicitas Escher
Journal:  J Clin Med       Date:  2021-04-29       Impact factor: 4.241

3.  Long-Term Prognosis of Suspected Myocarditis and Cardiomyopathy Associated with Viral Infection of the Myocardial Tissue: A Meta-Analysis of Cohort Studies.

Authors:  Wen-Hao Chen; You-Sheng Guo; Dong-Hui Zhang; Huan-Ji Zhang
Journal:  Cardiovasc Ther       Date:  2019-12-16       Impact factor: 3.023

4.  Detection of parvovirus mRNAs as markers for viral activity in endomyocardial biopsy-based diagnosis of patients with unexplained heart failure.

Authors:  Heiko Pietsch; Felicitas Escher; Ganna Aleshcheva; Dirk Lassner; Claus-Thomas Bock; Heinz-Peter Schultheiss
Journal:  Sci Rep       Date:  2020-12-18       Impact factor: 4.379

5.  Intravenous immunoglobulin therapy in adult patients with idiopathic chronic cardiomyopathy and cardiac parvovirus B19 persistence: a prospective, double-blind, randomized, placebo-controlled clinical trial.

Authors:  Mark R Hazebroek; Michiel T H M Henkens; Anne G Raafs; Job A J Verdonschot; Jort J Merken; Robert M Dennert; Casper Eurlings; Myrurgia A Abdul Hamid; Petra F G Wolffs; Bjorn Winkens; Hans-Peter Brunner-La Rocca; Christian Knackstedt; Pieter van Paassen; Vanessa P M van Empel; Stephane R B Heymans
Journal:  Eur J Heart Fail       Date:  2021-01-07       Impact factor: 15.534

6.  Interferon-β Suppresses Transcriptionally Active Parvovirus B19 Infection in Viral Cardiomyopathy: A Subgroup Analysis of the BICC-Trial.

Authors:  Heinz-Peter Schultheiss; Claus-Thomas Bock; Ganna Aleshcheva; Christian Baumeier; Wolfgang Poller; Felicitas Escher
Journal:  Viruses       Date:  2022-02-21       Impact factor: 5.048

7.  The Spontaneous Course of Human Herpesvirus 6 DNA-Associated Myocarditis and the Effect of Immunosuppressive Intervention.

Authors:  Ahmed Elsanhoury; Uwe Kühl; Bruno Stautner; Oliver Klein; Alexander Krannich; Daniel Morris; Monika Willner; Ewa Jankowska; Karin Klingel; Sophie Van Linthout; Carsten Tschöpe
Journal:  Viruses       Date:  2022-01-31       Impact factor: 5.818

Review 8.  Myocarditis and inflammatory cardiomyopathy: current evidence and future directions.

Authors:  Carsten Tschöpe; Enrico Ammirati; Biykem Bozkurt; Alida L P Caforio; Leslie T Cooper; Stephan B Felix; Joshua M Hare; Bettina Heidecker; Stephane Heymans; Norbert Hübner; Sebastian Kelle; Karin Klingel; Henrike Maatz; Abdul S Parwani; Frank Spillmann; Randall C Starling; Hiroyuki Tsutsui; Petar Seferovic; Sophie Van Linthout
Journal:  Nat Rev Cardiol       Date:  2020-10-12       Impact factor: 49.421

Review 9.  Cardiovascular consequences of viral infections: from COVID to other viral diseases.

Authors:  Heinz-Peter Schultheiss; Christian Baumeier; Heiko Pietsch; C-Thomas Bock; Wolfgang Poller; Felicitas Escher
Journal:  Cardiovasc Res       Date:  2021-11-22       Impact factor: 10.787

10.  Transcriptional Active Parvovirus B19 Infection Predicts Adverse Long-Term Outcome in Patients with Non-Ischemic Cardiomyopathy.

Authors:  Felicitas Escher; Ganna Aleshcheva; Heiko Pietsch; Christian Baumeier; Ulrich M Gross; Benedikt Norbert Schrage; Dirk Westermann; Claus-Thomas Bock; Heinz-Peter Schultheiss
Journal:  Biomedicines       Date:  2021-12-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.